Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older
- People who have been diagnosed (confirmed by laboratory analysis of tissue) with either advanced-stage epithelial ovarian cancer, advanced-stage primary peritoneal carcinomatosis (a cancer affecting the lining of the abdomen), or advanced-stage fallopian tube carcinoma — whether newly diagnosed or returned after previous treatment
- People who had a tissue or fluid sample taken from the tumour or abdominal area before starting chemotherapy, which was used for a specific laboratory test called the ChemoINTEL assay
- People who have received at least 3 cycles of standard chemotherapy for their condition, using one or more of the following drugs: Carboplatin, Cisplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Ifosfamide, Irinotecan, Oxaliplatin, Paclitaxel, Pemetrexed, Topotecan, Vinorelbine, or Bevacizumab (Avastin)
- People who have had their response to treatment assessed after their third and sixth chemotherapy cycles, using standard measurement methods
- People who have signed a consent form agreeing to take part in the trial
Who may not be able to join:
- People who have not signed the required consent form to participate
- People whose cancer is a type other than advanced-stage epithelial ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube carcinoma
- People who did not receive standard chemotherapy from the list of drugs specified above
- People whose tissue or fluid sample did not contain enough living cells to complete the minimum required ChemoINTEL laboratory testing for Carboplatin, Cisplatin, Docetaxel, and Paclitaxel
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Henry, Pierian Biosciences Ltd
Phone: +44 (0)333 034 1690
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prediction Algorithm
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.